Glenmark Pharmaceuticals
Dr. Nikhil Amin is responsible for driving Glenmark’s research and development efforts, and also heads the newly formed Innovative Medicines Group that focuses on the discovery and development of novel medicines. Dr. Amin is a Certified Pulmonologist from the American Board of Pediatrics, with over twenty-five years of Academic, Research and Pharmaceutical Industry experience as a Head of R&D and Clinical Development. He is a well-respected faculty within academia and research in the fields of Respiratory (including cystic fibrosis, asthma, COPD, pulmonary hypertension), Metabolism (diabetes mellitus, osteopenia), Inflammation, Pain, and Inhaled Vaccines.
Prior to joining Glenmark, Dr. Amin was the Global Clinical Lead – Inflammation and Immunology at Regeneron Pharmaceuticals Inc. He has also previously held positions of increasing seniority at MannKind Corporation, Paramus, New Jersey as well as academic positions at New York Medical College, Valhalla, New York.
Dr. Amin holds Fellowships in Pediatric Pulmonology and General Academic Pediatrics from the New York Medical College, NY, USA, as well as an M.D. in Pediatrics from The Maharaja Sayajirao University, Baroda, India.
This person is not in any offices
Glenmark Pharmaceuticals
5 followers
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.